University of Pennsylvania researchers compared adults with type 2 diabetes starting GLP-1 drugs against other treatments and found a higher hair loss risk.
Recap by typeshit. Post by @science__sphere on Instagram.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
The post notes that much of the worry over semaglutide and cancer traces back to animal studies, and that a label warning differs from evidence of harm in people.
Dissolving strips are showing up in the peptide market. The Bee asks the FDA and researchers whether they are safe and actually work.
Loading…